Mediart Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 19-12-2024
- Company Age 9 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.06 Cr
as on 19-12-2024
- Revenue 29.80%
(FY 2024)
- Profit 6.53%
(FY 2024)
- Ebitda 14.68%
(FY 2024)
- Net Worth 10.30%
(FY 2024)
- Total Assets 41.46%
(FY 2024)
About Mediart Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹4.06 Cr.
Rajesh Kaul and Ruby Gogia serve as directors at the Company.
- CIN/LLPIN
U51109DL2015PTC286671
- Company No.
286671
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Oct 2015
- Date of AGM
09 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Mediart Lifesciences Private Limited offer?
Mediart Lifesciences Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Kidney Drugs, Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Immunosuppressive Drugs, Health Conditions, Kidney Care.
Who are the key members and board of directors at Mediart Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Kaul  | Director | 21-Oct-2015 | Current |
| Ruby Gogia | Director | 03-Sep-2016 | Current |
Financial Performance of Mediart Lifesciences.
Mediart Lifesciences Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 29.8% increase. The company also saw a slight improvement in profitability, with a 6.53% increase in profit. The company's net worth Soared by an impressive increase of 10.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mediart Lifesciences?
In 2024, Mediart Lifesciences had a public holding of 58.75%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 26 Aug 2020 | ₹4.06 Cr | Open |
How Many Employees Work at Mediart Lifesciences?
Mediart Lifesciences has a workforce of 71 employees as of Dec 19, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mediart Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mediart Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
